Kindred Biosciences Statistics
Share Statistics
Kindred Biosciences has 0
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -7.17 and the forward
PE ratio is null.
Kindred Biosciences's PEG ratio is
0.12.
| PE Ratio | -7.17 |
| Forward PE | n/a |
| PS Ratio | 4.02 |
| Forward PS | n/a |
| PB Ratio | 2.51 |
| P/FCF Ratio | -12.55 |
| PEG Ratio | 0.12 |
Financial Ratio HistoryEnterprise Valuation
Kindred Biosciences has an Enterprise Value (EV) of 178.15M.
| EV / Sales | 4.23 |
| EV / EBITDA | -11.65 |
| EV / EBIT | -18.07 |
| EV / FCF | -13.2 |
Financial Position
The company has a current ratio of 9.08,
with a Debt / Equity ratio of 0.3.
| Current Ratio | 9.08 |
| Quick Ratio | 9.05 |
| Debt / Equity | 0.3 |
| Debt / EBITDA | -1.34 |
| Debt / FCF | -1.51 |
| Interest Coverage | -10.92 |
Financial Efficiency
Return on Equity is -35.01% and Return on Invested Capital is -24.62%.
| Return on Equity | -35.01% |
| Return on Assets | -24.66% |
| Return on Invested Capital | -24.62% |
| Revenue Per Employee | $669,269.84 |
| Profits Per Employee | $-374,984.13 |
| Employee Count | 63 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 22.35 |
Taxes
| Income Tax | 1.83M |
| Effective Tax Rate | -8.39% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 1.32, so Kindred Biosciences's
price volatility has been higher than the market average.
| Beta | 1.32 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,505,521 |
Income Statement
In the last 12 months, Kindred Biosciences had revenue of 42.16M
and earned -23.62M
in profits. Earnings per share was -0.6.
| Revenue | 42.16M |
| Gross Profit | 37.54M |
| Operating Income | -19.97M |
| Net Income | -23.62M |
| EBITDA | -15.29M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.6 |
Full Income StatementBalance Sheet
The company has 11.62M in cash and 20.44M in
debt, giving a net cash position of -8.82M.
| Cash & Cash Equivalents | 11.62M |
| Total Debt | 20.44M |
| Net Cash | -8.82M |
| Retained Earnings | -244.85M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -9.86M
and capital expenditures -3.64M, giving a free cash flow of -13.49M.
| Operating Cash Flow | -9.86M |
| Capital Expenditures | -3.64M |
| Free Cash Flow | -13.49M |
| FCF Per Share | -0.34 |
Full Cash Flow StatementMargins
Gross margin is 89.03%, with operating and profit margins of -47.36% and -56.03%.
| Gross Margin | 89.03% |
| Operating Margin | -47.36% |
| Pretax Margin | -51.69% |
| Profit Margin | -56.03% |
| EBITDA Margin | -36.27% |
| EBIT Margin | -47.36% |
| FCF Margin | -32.01% |
